Making Real World Evidence Less 'Messy' To Help With Drug Pricing

The Medicines Company's inclisirin CV trial is 100-fold cheaper with digitized records, while Lilly is still hunting for a good HBA1C dataset, and Merck worries about "idiosyncratic" data.

FTI real world evidence Panel
Mark Nagy, Eli Lilly; Susan Shiff, Merck; Clive Meanwell, The Medicines Co. • Source: Photo by Brenda Sandburg

How does real world evidence fit into value-based pricing? A panel of pharmaceutical executives shed light on the issue during the FT Pharma Pricing and Value Summit held in New York Sept. 13.

Susan Shiff, senior VP, Center for Observational and Real-World Evidence at Merck & Co. Inc., said the question concerns...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Pricing Debate

More from Market Access

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.

PCMA, CVS, Cigna File Lawsuits Over ‘Dangerous’ Arkansas PBM Law

 
• By 

The suits are an early test of the Arkansas law banning company ownership of PBMs and pharmacies in the state, as other states consider similar legislation.

Medicare Part D LIS Access Threatened By House Budget Bill’s Medicaid Obstacles

 
• By 

An unintended consequence of a provision framed as an administrative change in the bill could significantly reduce medication adherence among low-income older adults and increase mortality, a study found.